Apalutamide-induced life-threatening dermatologic toxicity: Clinical histopathological correlations and salvage therapies in four cases: Case report series

This case report highlights the importance of recognizing and managing apalutamide-associated skin AEs. The development of these AEs appears to be dose-dependent, and early discontinuation or dose reduction of the drug is crucial for controlling the symptoms. A multidisciplinary approach involving oncologists and dermatologists is recommended to optimize the treatment strategy and maintain the patients' quality of life.